EVH (Evolent Health) COGS-to-Revenue : 0.79 (As of Mar. 2025)

View and export this data going back to 2015. Start your Free Trial

What is Evolent Health COGS-to-Revenue?

Evolent Health's Cost of Goods Sold for the three months ended in Mar. 2025 was $381 Mil. Its Revenue for the three months ended in Mar. 2025 was $484 Mil.

Evolent Health's COGS to Revenue for the three months ended in Mar. 2025 was 0.79.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Evolent Health's Gross Margin % for the three months ended in Mar. 2025 was 21.19%.

Evolent Health COGS-to-Revenue Historical Data

The historical data trend for Evolent Health's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evolent Health COGS-to-Revenue Chart

Evolent Health Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

Get a 7-Day Free Trial

0.75

0.72

0.77

0.86

Evolent Health Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
COGS-to-Revenue	Get a 7-Day Free Trial															0.84	0.83	0.87	0.88	0.79

Evolent Health COGS-to-Revenue Calculation

Evolent Health's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	2187.388	/	2554.741
	=	0.86

Evolent Health's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	381.178	/	483.649
	=	0.79

Evolent Health (NYSE:EVH) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Evolent Health's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	381.178 / 483.649
	=	21.19 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Evolent Health COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Evolent Health's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Evolent Health Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Evolent Health Inc (NYSE:EVH) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

9EH:Germany 9EH:Germany

Address

1812 N. Moore Street, Suite 1705, Arlington, VA, USA, 22209

Website

https://www.evolenthealth.com

Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.

Executives

Richard M Jelinek	director	40 W 47TH STREET, FLOOR 33, NEW YORK NY 10035
Kim Keck	director	30 W. MONROE STREET, SUITE 1200, CHICAGO IL 60603
Peter J Grua	director	C/O HLM VENTURE PARTNERS, 800 SOUTH STREET, SUITE 620, WALTHAM MA 02453
Daniel Joseph Mccarthy	officer: PRESIDENT	800 N GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Craig A. Barbarosh	director	3525 PIEDMONT RD., NE, BUILDING 6, SUITE 700, ATLANTA GA 30305
Seth Blackley	officer: President	800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Diane Holder	director	800 GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
John Paul Johnson	officer: Chief Financial Officer	800 NORTH GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Emily Ann Rafferty	officer: Chief Operating Officer	800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Jonathan Weinberg	officer: General Counsel	800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Toyin Ajayi	director	800 NORTH GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Cheryl Scott	director	800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Mary Bridget Duffy	director	C/O VOCERA COMMUNICATIONS, INC., 525 RACE STREET, SAN JOSE CA 95126
Frank J Williams	director, officer: Chief Executive Officer	800 NORTH GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Steve Tutewohl	officer: Chief Operating Officer	800 NORTH GLEBE ROAD, SUITE 500, ARLINGTON VA 22203